|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choueiri TK and Motzer RJ: Systemic
therapy for metastatic renal-cell carcinoma. N Engl J Med.
376:354–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Srigley JR, Delahunt B, Eble JN, Egevad L,
Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, et
al: The international society of urological pathology (ISUP)
Vancouver classification of renal Neoplasia. Am J Surg Pathol.
37:1469–1489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nickerson ML, Jaeger E, Shi Y, Durocher
JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko
V, et al: Improved identification of von Hippel-Lindau gene
alterations in clear cell renal tumors. Clin Cancer Res.
14:4726–4734. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Powles T, Albiges L, Staehler M, Bensalah
K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, et
al: Updated European association of urology guidelines
recommendations for the treatment of first-line metastatic clear
cell renal cancer. Eur Urol. Dec 7–2017.doi:
10.1016/j.eururo.2017.11.016 (Epub ahead of print).
|
|
6
|
Powles T, Staehler M, Ljungberg B,
Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M,
Kuczyk MA, et al: Updated EAU Guidelines for clear cell renal
cancer patients who fail vegf targeted therapy. Eur Urol. 69:4–6.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karakiewicz PI, Briganti A, Chun FK, Trinh
QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J,
Mulders PF, et al: Multi-institutional validation of a new renal
cancer-specific survival nomogram. J Clin Oncol. 25:1316–1322.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garcia-Martin E, Martinez C,
Alonso-Navarro H, Benito-León J, Lorenzo-Betancor O, Pastor P,
Puertas I, Rubio L, López-Alburquerque T, Agúndez JA and
Jiménez-Jiménez FJ: Gamma-aminobutyric acid GABRA4, GABRE, and
GABRQ receptor polymorphisms and risk for essential tremor.
Pharmacogenet Genomics. 21:436–439. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neelands TR, Zhang J and Macdonald RL:
GABA(A) receptors expressed in undifferentiated human
teratocarcinoma NT2 cells differ from those expressed by
differentiated NT2-N cells. J Neurosci. 19:7057–7065. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haydar TF, Wang F, Schwartz ML and Rakic
P: Differential modulation of proliferation in the neocortical
ventricular and subventricular zones. J Neurosci. 20:5764–5774.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li YH, Liu Y, Li YD, Liu YH, Li F, Ju Q,
Xie PL and Li GC: GABA stimulates human hepatocellular carcinoma
growth through overexpressed GABAA receptor theta subunit. World J
Gastroenterol. 18:2704–2711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
International Cancer Genome Consortium, ;
Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan
MK, Calvo F, Eerola I, et al: International network of cancer
genome projects. Nature. 464:993–998. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cancer Genome Atlas Research Network, ;
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ha M, Han ME, Kim JY, Jeong DC, Oh SO and
Kim YH: Prognostic role of TPD52 in acute myeloid leukemia: A
retrospective multicohort analysis. J Cell Biochem. 120:3672–3678.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han ME, Kim JY, Kim GH, Park SY, Kim YH
and Oh SO: SAC3D1: A novel prognostic marker in hepatocellular
carcinoma. Sci Rep. 8:156082018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cho SH, Pak K, Jeong DC, Han ME, Oh SO and
Kim YH: The AP2M1 gene expression is a promising biomarker for
predicting survival of patients with hepatocellular carcinoma. J
Cell Biochem. 120:4140–4146. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim YH, Jeong DC, Pak K, Goh TS, Lee CS,
Han ME, Kim JY, Liangwen L, Kim CD, Jang JY, et al: Gene network
inherent in genomic big data improves the accuracy of prognostic
prediction for cancer patients. Oncotarget. 8:77515–77526.
2017.PubMed/NCBI
|
|
20
|
Uno H, Cai T, Pencina MJ, D'Agostino RB
and Wei LJ: On the C-statistics for evaluating overall adequacy of
risk prediction procedures with censored survival data. Stat Med.
30:1105–1117. 2011.PubMed/NCBI
|
|
21
|
Hoshida Y, Nijman SM, Kobayashi M, Chan
JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K,
Hashimoto M, et al: Integrative transcriptome analysis reveals
common molecular subclasses of human hepatocellular carcinoma.
Cancer Res. 69:7385–7392. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shtraizent N, DeRossi C, Nayar S,
Sachidanandam R, Katz LS, Prince A, Koh AP, Vincek A, Hadas Y,
Hoshida Y, et al: MPI depletion enhances O-GlcNAcylation of p53 and
suppresses the Warburg effect. Elife. 6(pii): e224772017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Subramanian P and Haas NB: Recent advances
in localized RCC: A focus on VEGF and immuno-oncology therapies.
Urol Oncol. 36:23–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Chen L, Wang G, Cheng S, Qian K,
Liu X, Wu CL, Xiao Y and Wang X: Fifteen hub genes associated with
progression and prognosis of clear cell renal cell carcinoma
identified by coexpression analysis. J Cell Physiol.
234:10225–10237. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guan L, Tan J, Li H and Jin X: Biomarker
identification in clear cell renal cell carcinoma based on
miRNA-seq and digital gene expression-seq data. Gene. 647:205–212.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao C, Zhou C, Zhuang J, Liu L, Liu C, Li
H, Liu G, Wei J and Sun C: MicroRNA expression in cervical cancer:
Novel diagnostic and prognostic biomarkers. J Cell Biochem.
119:7080–7090. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Joseph J, Niggemann B, Zaenker KS and
Entschladen F: The neurotransmitter gamma-aminobutyric acid is an
inhibitory regulator for the migration of SW 480 colon carcinoma
cells. Cancer Res. 62:6467–6469. 2002.PubMed/NCBI
|
|
28
|
Azuma H, Inamoto T, Sakamoto T, Kiyama S,
Ubai T, Shinohara Y, Maemura K, Tsuji M, Segawa N, Masuda H, et al:
Gamma-aminobutyric acid as a promoting factor of cancer metastasis;
induction of matrix metalloproteinase production is potentially its
underlying mechanism. Cancer Res. 63:8090–8096. 2003.PubMed/NCBI
|
|
29
|
Plummer PN, Colson NJ, Lewohl JM, MacKay
RK, Fernandez F, Haupt LM and Griffiths LR: Significant differences
in gene expression of GABA receptors in peripheral blood leukocytes
of migraineurs. Gene. 490:32–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wittner BS, Sgroi DC, Ryan PD, Bruinsma
TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, et
al: Analysis of the MammaPrint breast cancer assay in a
predominantly postmenopausal cohort. Clin Cancer Res. 14:2988–2993.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen HY, Yu SL, Chen CH, Chang GC, Chen
CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, et al: A five-gene
signature and clinical outcome in non-small-cell lung cancer. N
Engl J Med. 356:11–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goh TS, Lee JS, II Kim J, Park YG, Pak K,
Jeong DC, Oh SO and Kim YH: Prognostic scoring system for
osteosarcoma using network-regularized high-dimensional
Cox-regression analysis and potential therapeutic targets. J Cell
Physiol. 234:13851–13857. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pak K, Kim YH, Suh S, Goh TS, Jeong DC,
Kim SJ, Kim IJ, Han ME and Oh SO: Development of a risk scoring
system for patients with papillary thyroid cancer. J Cell Mol Med.
23:3010–3015. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim YH, Jeong DC, Pak K, Han ME, Kim JY,
Liangwen L, Kim HJ, Kim TW, Kim TH, Hyun DW and Oh SO: SLC2A2
(GLUT2) as a novel prognostic factor for hepatocellular carcinoma.
Oncotarget. 8:68381–68392. 2017.PubMed/NCBI
|
|
36
|
Nault JC, De Reynies A, Villanueva A,
Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud
S, Rousseau F, et al: A hepatocellular carcinoma 5-gene score
associated with survival of patients after liver resection.
Gastroenterology. 145:176–187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
van't Veer LJ, Dai H, van de Vijver MJ, He
YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
